Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Value-Added Medicines

Set Alert for Value-Added Medicines

Sandoz Phases US Epinephrine Entry

Sandoz will first focus on the US institutional channel on which it is increasingly concentrating its attention as it rolls out its alternative to Mylan’s EpiPen epinephrine auto-injector.
Value-Added Medicines Launches

Dr Reddy’s Growth Strategy Sets Sights On Six Spaces

Dr Reddy’s chief operating officer Erez Israeli says six key areas – the US, China, Russia, India, APIs and hospital drugs – underpin the Indian company’s growth ambitions, with small-molecule generics remaining the firm’s “bread and butter”.

United States India

Kashiv Pharma Swallows Up Adello Biologics, Becoming Kashiv BioSciences

New Jersey-based Kashiv adds biosimilar assets to its repertoire by acquiring Adello Biologics, becoming, in its own words, a “fully-integrated biosciences company with an expanded and dynamic platform for growth.” Adello’s CEO, Chintu Patel, will lead the combination.

M & A Biosimilars

Mayne Lines Up Two, But Misses Out On Myring

Mayne Pharma intends in January to introduce novel formulations of itraconazole and halobetasol in the US; but the Australian firm has been hit in its attempt to bring the Myring generic to the US market.
Value-Added Medicines Infectious Diseases

Sandoz Forms Insulin Biosimilars Deal With Gan & Lee

In line with its strategy to expand its biosimilars business, Sandoz has entered into an agreement with China’s Gan & Lee to market and supply three insulin biosimilars in the EU, US, and other key territories.

Biosimilars Metabolic Disorders

Pfizer Receives CHMP Backing On EU Bevacizumab And Withdraws Skinny Label Adalimumab UPDATED

Pfizer was at the forefront of the CHMP’s December 2018 meeting concerning biosimilars, while Dipharma and PARI Pharma were backed on a generic and hybrid medicine apiece.

Advisory Committees Biosimilars
See All
UsernamePublicRestriction

Register